Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

IMJUDO 20 mg/ml concentrate for solution for infusion {equilateral_black_triangle}

Active Ingredient:
tremelimumab
Company:  
AstraZeneca UK Limited See contact details
ATC code: 
L01FX20
{info_black}
About Medicine
{healthcare_pro_orange} This information is for use by healthcare professionals
Last updated on emc: 19 Feb 2024

 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. Name of the medicinal product

IMJUDO 20 mg/ml concentrate for solution for infusion.

2. Qualitative and quantitative composition

Each mL of concentrate for solution for infusion contains 20 mg of tremelimumab.

One vial of 1.25 ml of concentrate contains 25 mg of tremelimumab.

One vial of 15 ml of concentrate contains 300 mg of tremelimumab.

Tremelimumab is a human anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) immunoglobulin G2-IgG2a monoclonal antibody produced in murine myeloma cells by recombinant DNA technology.

For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Concentrate for solution for infusion (sterile concentrate).

Clear to slightly opalescent, colourless to slightly yellow solution, free from or practically free from visible particles. The solution has a pH of approximately 5.5 and an osmolality of approximately 285 mOsm/kg.

4. Clinical particulars
4.1 Therapeutic indications

IMJUDO in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).

4.2 Posology and method of administration

Treatment must be initiated and supervised by a physician experienced in the treatment of cancer.

Posology

The recommended dose of IMJUDO is presented in Table 1. IMJUDO is administered as an intravenous infusion over 1 hour.

Table 1. Recommended dose of IMJUDO

Indication

Recommended IMJUDO dosage

Duration of Therapy

Advanced or unresectable HCC

IMJUDO 300 mga as a single dose administered in combination with durvalumab 1500 mga at Cycle 1/Day 1, followed by durvalumab monotherapy every 4 weeks

Until disease progression or unacceptable toxicity.

a For IMJUDO, HCC patients with a body weight of 40 kg or less must receive weight-based dosing, equivalent to IMJUDO 4 mg/kg until weight is greater than 40 kg. For durvalumab, patients with a body weight of 30 kg or less must receive weight-based dosing, equivalent to durvalumab 20 mg/kg until weight is greater than 30 kg.

Dose escalation or reduction is not recommended during treatment with IMJUDO in combination with durvalumab. Treatment withholding or discontinuation may be required based on individual safety and tolerability.

Guidelines for management of immune-mediated adverse reactions are described in Table 2 (see section 4.4). Refer also to the SmPC for durvalumab.

Table 2. Treatment modifications and management recommendations for IMJUDO in combination with durvalumab

Adverse reactions

Severitya

Treatment modification

Corticosteroid treatment unless otherwise specifiedb

Immune-mediated pneumonitis/interstitial lung disease

Grade 2

Withhold dosec

Initiate 1 to 2 mg/kg/day prednisone or equivalent followed by a taper

Grade 3 or 4

Permanently discontinue

Immune-mediated hepatitis

ALT or AST > 3 - ≤ 5 x ULN or total bilirubin > 1.5 - ≤ 3 x ULN

Withhold dosec

Initiate 1 to 2 mg/kg/day prednisone or equivalent followed by a taper

ALT or AST > 5 - ≤ 10 x ULN

Withhold durvalumab and permanently discontinue IMJUDO (where appropriate)

Concurrent ALT or AST > 3 x ULN and total bilirubin > 2 x ULNd

Permanently discontinue

ALT or AST > 10 x ULN or total bilirubin > 3 x ULN

Immune-mediated hepatitis in HCC (or secondary tumour involvement of the liver with abnormal baseline values)e

ALT or AST > 2.5 - ≤ 5 x BLV and ≤ 20 x ULN

Withhold dosec

Initiate 1 to 2 mg/kg/day prednisone or equivalent followed by a taper

ALT or AST > 5 - 7 x BLV and ≤ 20 x ULN

or

concurrent ALT or AST 2.5 - 5 x BLV and ≤ 20 x ULN and total bilirubin > 1.5 - < 2 x ULNd

Withhold durvalumab and permanently discontinue IMJUDO (where appropriate)

ALT or AST > 7 x BLV or > 20 x ULN whichever occurs first or bilirubin > 3 x ULN

Permanently discontinue

Immune-mediated colitis or diarrhoea

Grade 2

Withhold dosec

Initiate 1 to 2 mg/kg/day prednisone or equivalent followed by a taper

Grade 3 or 4

Permanently discontinue

Intestinal perforation

ANY grade

Permanently discontinue

Consult a surgeon immediately if an intestinal perforation is suspected

Immune-mediated hyperthyroidism, thyroiditis

Grade 2-4

Withhold dose until clinically stable

Symptomatic management

Immune-mediated hypothyroidism

Grade 2-4

No changes

Initiate thyroid hormone replacement as clinically indicated

Immune-mediated adrenal insufficiency, hypophysitis/hypopituitarism

Grade 2-4

Withhold dose until clinically stable

Initiate 1 to 2 mg/kg/day prednisone or equivalent followed by a taper and hormone replacement as clinically indicated

Immune-mediated Type 1 diabetes mellitus

Grade 2-4

No changes

Initiate treatment with insulin as clinically indicated

Immune-mediated nephritis

Grade 2 with serum creatinine > 1.5-3 x (ULN or baseline)

Withhold dosec

Initiate 1 to 2 mg/kg/day prednisone or equivalent followed by a taper

Grade 3 with serum creatinine > 3 x baseline or > 3-6 x ULN; Grade 4 with serum creatinine > 6 x ULN

Permanently discontinue

Immune-mediated rash or dermatitis (including pemphigoid)

Grade 2 for > 1 week or Grade 3

Withhold dosec

Initiate 1 to 2 mg/kg/day prednisone or equivalent followed by a taper

Grade 4

Permanently discontinue

Immune-mediated myocarditis

Grade 2-4

Permanently discontinue

Initiate 2 to 4 mg/kg/day prednisone or equivalent followed by a taperf

Immune-mediated myositis/polymyositis

Grade 2 or 3

Withhold dosec,g

Initiate 1 to 2 mg/kg/day prednisone or equivalent followed by a taper

Grade 4

Permanently discontinue

Infusion-related reactions

Grade 1 or 2

Interrupt or slow the rate of infusion

May consider pre-medications for prophylaxis of subsequent infusion reactions

Grade 3 or 4

Permanently discontinue

Manage severe infusion-related reactions per institutional standard, appropriate clinical practice guidelines and/or society guidelines

Immune-mediated myasthenia gravis

Grade 2-4

Permanently discontinue

Initiate 1 to 2 mg/kg/day prednisone or equivalent followed by a taper

Immune-mediated meningitis

Grade 2

Withhold dosec

Initiate 1 to 2 mg/kg/day prednisone or equivalent followed by a taper

Grade 3 or 4

Permanently discontinue

Immune-mediated encephalitis

Grade 2-4

Permanently discontinue

Initiate 1 to 2 mg/kg/day prednisone or equivalent followed by a taper

Immune-mediated Guillain-Barré syndrome

Grade 2-4

Permanently discontinue

Initiate 1 to 2 mg/kg/day prednisone or equivalent followed by a taper

Other immune-mediated adverse reactionsh

Grade 2 or 3

Withhold dosec

Initiate 1 to 2 mg/kg/day prednisone or equivalent followed by a taper

Grade 4

Permanently discontinue

Non-immune-mediated adverse reactions

Grade 2 and 3

Withhold dose until ≤ Grade 1 or return to baseline

Grade 4

Permanently discontinue i

a Common Terminology Criteria for Adverse Events, version 4.03. ALT: alanine aminotransferase; AST: aspartate aminotransferase; ULN: upper limit of normal; BLV: baseline value.

b Upon improvement to ≤ Grade 1, corticosteroid taper should be initiated and continued over at least 1 month. Consider increasing dose of corticosteroids and/or using additional systemic immunosuppressants if there is worsening or no improvement.

c After withholding, IMJUDO and/or durvalumab can be resumed within 12 weeks if the adverse reactions improved to ≤ Grade 1 and the corticosteroid dose has been reduced to ≤ 10 mg prednisone or equivalent per day. IMJUDO and durvalumab should be permanently discontinued for recurrent Grade 3 adverse reactions, as applicable.

d For patients with alternative cause follow the recommendations for AST or ALT increases without concurrent bilirubin elevations.

e If AST and ALT are less than or equal to ULN at baseline in patients with liver involvement, withhold or permanently discontinue durvalumab based on recommendations for hepatitis with no liver involvement.

f If no improvement within 2 to 3 days despite corticosteroids, promptly start additional immunosuppressive therapy. Upon resolution (Grade 0), corticosteroid taper should be initiated and continued over at least 1 month.

g Permanently discontinue IMJUDO and durvalumab if the adverse reaction does not resolve to ≤ Grade 1 within 30 days or if there are signs of respiratory insufficiency.

h Includes immune thrombocytopenia, pancreatitis, cystitis noninfective, immune-mediated arthritis, and uveitis.

i With the exception of Grade 4 laboratory abnormalities, about which the decision to discontinue treatment should be based on accompanying clinical signs/symptoms and clinical judgment.

For suspected immune-mediated adverse reactions, adequate evaluation should be performed to confirm aetiology or exclude alternate aetiologies.

Special populations

Paediatric population

The safety and efficacy of IMJUDO in children and adolescents below 18 years of age have not been established. No data are available.

Elderly

No dose adjustment is required for elderly patients (≥ 65 years of age) (see section 5.2).

Renal impairment

No dose adjustment of IMJUDO is recommended in patients with mild or moderate renal impairment. Data from patients with severe renal impairment are too limited to draw conclusions on this population (see section 5.2).

Hepatic impairment

No dose adjustment of IMJUDO is recommended for patients with mild or moderate hepatic impairment. IMJUDO has not been studied in patients with severe hepatic impairment (see section 5.2).

Method of administration

IMJUDO is for intravenous use, it is administered as an intravenous infusion after dilution, over 1 hour (see section 6.6).

For instructions on dilution of the medicinal product before administration, see section 6.6.

IMJUDO in combination with durvalumab

When IMJUDO is given in combination with durvalumab, administer IMJUDO as a separate intravenous infusion prior to durvalumab on the same day. Refer to the SmPC for durvalumab administration information.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Traceability

In order to improve the traceability of biological medicinal products, the tradename and the batch number of the administered product should be clearly recorded.

Immune-mediated pneumonitis

Immune-mediated pneumonitis or interstitial lung disease, defined as requiring use of systemic corticosteroids and with no clear alternate aetiology, occurred in patients receiving tremelimumab in combination with durvalumab (see section 4.8). Patients should be monitored for signs and symptoms of pneumonitis. Suspected pneumonitis should be confirmed with radiographic imaging and other infectious and disease-related aetiologies excluded, and managed as recommended in section 4.2.

Immune-mediated hepatitis

Immune-mediated hepatitis, defined as requiring use of systemic corticosteroids and with no clear alternate aetiology, occurred in patients receiving tremelimumab in combination with durvalumab (see section 4.8). Monitor alanine aminotransferase, aspartate aminotransferase, total bilirubin, and alkaline phosphatase levels prior to initiation of treatment and prior to each subsequent infusion. Additional monitoring is to be considered based on clinical evaluation. Immune-mediated hepatitis should be managed as recommended in section 4.2.

Immune-mediated colitis

Immune-mediated colitis or diarrhoea, defined as requiring use of systemic corticosteroids and with no clear alternate aetiology, occurred in patients receiving tremelimumab in combination with durvalumab (see section 4.8). Intestinal perforation and large intestine perforation were reported in patients receiving tremelimumab in combination with durvalumab. Patients should be monitored for signs and symptoms of colitis/diarrhoea and intestinal perforation and managed as recommended in section 4.2.

Immune-mediated endocrinopathies

Immune-mediated hypothyroidism, hyperthyroidism and thyroiditis

Immune-mediated hypothyroidism, hyperthyroidism and thyroiditis occurred in patients receiving tremelimumab in combination with durvalumab, and hypothyroidism may follow hyperthyroidism (see section 4.8). Patients should be monitored for abnormal thyroid function tests prior to and periodically during treatment and as indicated based on clinical evaluation. Immune-mediated hypothyroidism, hyperthyroidism, and thyroiditis should be managed as recommended in section 4.2.

Immune-mediated adrenal insufficiency

Immune-mediated adrenal insufficiency occurred in patients receiving tremelimumab in combination with durvalumab (see section 4.8). Patients should be monitored for clinical signs and symptoms of adrenal insufficiency. For symptomatic adrenal insufficiency, patients should be managed as recommended in section 4.2.

Immune-mediated type 1 diabetes mellitus

Immune-mediated type 1 diabetes mellitus, which can first present as diabetic ketoacidosis that can be fatal if not detected early, occurred in patients receiving tremelimumab in combination with durvalumab (see section 4.8). Patients should be monitored for clinical signs and symptoms of type 1 diabetes mellitus. For symptomatic type 1 diabetes mellitus, patients should be managed as recommended in section 4.2.

Immune-mediated hypophysitis/hypopituitarism

Immune-mediated hypophysitis or hypopituitarism occurred in patients receiving tremelimumab in combination with durvalumab (see section 4.8). Patients should be monitored for clinical signs and symptoms of hypophysitis or hypopituitarism. For symptomatic hypophysitis or hypopituitarism, patients should be managed as recommended in section 4.2.

Immune-mediated nephritis

Immune-mediated nephritis, defined as requiring use of systemic corticosteroids and with no clear alternate aetiology, occurred in patients receiving tremelimumab in combination with durvalumab (see section 4.8). Patients should be monitored for abnormal renal function tests prior to and periodically during treatment and managed as recommended in section 4.2.

Immune-mediated rash

Immune-mediated rash or dermatitis (including pemphigoid), defined as requiring use of systemic corticosteroids and with no clear alternate aetiology, occurred in patients receiving tremelimumab in combination with durvalumab (see section 4.8). Events of Stevens-Johnson Syndrome or toxic epidermal necrolysis have been reported in patients treated with PD-1 and CTLA-4 inhibitors. Patients should be monitored for signs and symptoms of rash or dermatitis and managed as recommended in section 4.2.

Immune-mediated myocarditis

Immune-mediated myocarditis, which can be fatal, occurred in patients receiving tremelimumab in combination with durvalumab (see section 4.8). Patients should be monitored for signs and symptoms of immune-mediated myocarditis and managed as recommended in section 4.2.

Other immune-mediated adverse reactions

Given the mechanism of action of tremelimumab in combination with durvalumab, other potential immune-mediated adverse reactions may occur. The following immune-related adverse reactions have been observed in patients treated with tremelimumab in combination with durvalumab: myasthenia gravis, myositis, polymyositis, meningitis, encephalitis, Guillain-Barré syndrome, immune thrombocytopenia, cystitis noninfective, immune-mediated arthritis and uveitis (see section 4.8). Patients should be monitored for signs and symptoms and managed as recommended in section 4.2.

Infusion-related reactions

Patients should be monitored for signs and symptoms of infusion-related reactions. Severe infusion-related reactions have been reported in patients receiving tremelimumab in combination with durvalumab (see section 4.8). Infusion-related reactions should be managed as recommended in section 4.2.

Patients excluded from clinical studies

Advanced or unresectable HCC

Patients with the following were excluded from clinical studies: Child-Pugh Score B or C, main portal vein thrombosis, liver transplant, uncontrolled hypertension, history of, or current brain metastases, spinal cord compression, co-infection of viral hepatitis B and hepatitis C, active or prior documented gastrointestinal (GI) bleeding within 12 months, ascites requiring non-pharmacologic intervention within 6 months, hepatic encephalopathy within 12 months before the start of treatment, active or prior documented autoimmune or inflammatory disorders. In the absence of data, tremelimumab should be used with caution in these populations after careful consideration of the potential benefit/risk on an individual basis.

Sodium content

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'.

4.5 Interaction with other medicinal products and other forms of interaction

The use of systemic corticosteroids or immunosuppressants before starting tremelimumab, except physiological dose of systemic corticosteroids (≤ 10 mg/day prednisone or equivalent), is not recommended because of their potential interference with the pharmacodynamic activity and efficacy of tremelimumab. However, systemic corticosteroids or other immunosuppressants can be used after starting tremelimumab to treat immune-related adverse reactions (see section 4.4).

No formal pharmacokinetic (PK) drug-drug interaction studies have been conducted with tremelimumab. Since the primary elimination pathways of tremelimumab are protein catabolism via reticuloendothelial system or target-mediated disposition, no metabolic drug-drug interactions are expected.

4.6 Fertility, pregnancy and lactation

Women of childbearing potential/Contraception

Women of childbearing potential should use effective contraception during treatment with tremelimumab and for at least 3 months after the last dose of tremelimumab.

Pregnancy

There are no data on the use of tremelimumab in pregnant women. Based on its mechanism of action, and placental transfer of human IgG2, tremelimumab has the potential to impact maintenance of pregnancy and may cause foetal harm when administered to a pregnant woman. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). IMJUDO is not recommended during pregnancy and in women of childbearing potential not using effective contraception during treatment and for at least 3 months after the last dose.

Breast-feeding

There is no information regarding the presence of tremelimumab in human milk, the absorption and effects on the breast-fed infant, or the effects on milk production. Human IgG2 is known to be excreted in human milk. A risk to the breastfed child cannot be excluded. Breast-feeding should be discontinued during treatment with IMJUDO and for at least 3 months after the last dose.

Fertility

There are no data on the potential effects of tremelimumab on fertility in humans or animals. However, mononuclear cell infiltration in prostate and uterus was observed in repeat-dose toxicity studies (see Section 5.3). The clinical relevance of these findings for fertility is unknown.

4.7 Effects on ability to drive and use machines

Tremelimumab has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

Summary of the safety profile

IMJUDO in combination with durvalumab

The safety of tremelimumab 300 mg as a single dose in combination with durvalumab, is based on pooled data in 462 HCC patients (HCC pool) from the HIMALAYA Study and another study in HCC patients, Study 22. The most common (> 10%) adverse reactions were rash (32.5%), pruritus (25.5%), diarrhoea (25.3%), abdominal pain (19.7%), aspartate aminotransferase increased/alanine aminotransferase increased (18.0%), pyrexia (13.9%), hypothyroidism (13.0%), cough/productive cough (10.8%) and oedema peripheral (10.4%). (see Table 3).

The most common (> 3%) severe adverse reactions (NCI CTCAE Grade ≥ 3) were aspartate aminotransferase increased/alanine aminotransferase increased (8.9%), lipase increased (7.1%), amylase increased (4.3%) and diarrhoea (3.9%).

The most common (> 2%) serious adverse reactions were colitis (2.6%), diarrhoea (2.4%) and pneumonia (2.2%).

The frequency of treatment discontinuation due to adverse reactions is 6.5%. The most common adverse reactions leading to treatment discontinuation were hepatitis (1.5%) and aspartate aminotransferase increased/alanine aminotransferase increased (1.3%).

Tabulated list of adverse reactions

Table 3, unless otherwise stated, lists the incidence of adverse reactions (ADRs) in patients treated with tremelimumab 300 mg in combination with durvalumab in the HCC pool of 462 patients.

Adverse reactions are listed according to system organ class in MedDRA. Within each system organ class, the ADRs are presented in decreasing frequency. The corresponding frequency category for each ADR is defined as: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1000); very rare (< 1/10,000); not known (cannot be estimated from available data). Within each frequency grouping, ADRs are presented in order of decreasing seriousness.

Table 3. Adverse reactions in patients treated with tremelimumab in combination with durvalumab

Tremelimumab 300 mg in combination with durvalumab

Any Grade (%)

Grade 3-4 (%)

Infections and infestations

Upper respiratory tract infectionsa

Common

8.4

0

Pneumoniab

Common

4.3

1.3

Influenza

Common

2.2

0

Oral candidiasis

Uncommon

0.6

0

Dental and oral soft tissue infectionsc

Common

1.3

0

Blood and lymphatic system disorders

Immune thrombocytopenia

Uncommond

0.3

0

Endocrine disorders

Hypothyroidisme

Very common

13.0

0

Hyperthyroidismf

Common

9.5

0.2

Adrenal insufficiency

Common

1.3

0.2

Hypopituitarism/Hypophysitis

Uncommon

0.9

0

Thyroiditisg

Common

1.7

0

Diabetes insipidus

Rareh

<0.1

0

Type 1 diabetes mellitus

Uncommonh

0.3

<0.1

Eye disorders

Uveitis

Rareh

<0.1

0

Nervous system disorders

Encephalitis

Rareh

<0.1

0

Myasthenia gravis

Uncommon

0.4

0

Guillain-Barré syndrome

Rarei

<0.1

0

Meningitis

Uncommon

0.2

0.2

Cardiac disorders

Myocarditisj

Uncommon

0.4

0

Respiratory, thoracic and mediastinal disorders

Cough/Productive cough

Very common

10.8

0.2

Pneumonitisk

Common

2.4

0.2

Dysphonia

Uncommon

0.9

0

Interstitial lung disease

Uncommon

0.2

0

Gastrointestinal disorders

Diarrhoea

Very common

25.3

3.9

Amylase increased

Common

8.9

4.3

Abdominal painl

Very common

19.7

2.2

Lipase increased

Common

10.0

7.1

Colitism

Common

3.5

2.6

Pancreatitisn

Common

1.3

0.6

Intestinal perforation

Rarei

<0.1

<0.1

Large intestine perforation

Uncommoni

0.1

<0.1

Hepatobiliary disorders

Aspartate aminotransferase increased/Alanine aminotransferase increasedo

Very common

18.0

8.9

Hepatitisp

Common

5.0

1.7

Skin and subcutaneous tissue disorders

Rashq

Very common

32.5

3.0

Pruritus

Very common

25.5

0

Dermatitisr

Common

1.3

0

Night sweats

Common

1.3

0

Pemphigoid

Uncommon

0.2

0

Musculoskeletal and connective tissue disorders

Myalgia

Common

3.5

0.2

Myositis

Uncommon

0.6

0.2

Polymyositis

Uncommon

0.2

0.2

Immune-mediated arthritis

Uncommon

0.6

0

Renal and urinary disorders

Blood creatinine increased

Common

4.5

0.4

Dysuria

Common

1.5

0

Nephritiss

Uncommon

0.6

0.4

Cystitis noninfective

Rareh

<0.1

0

General disorders and administration site conditions

Pyrexia

Very common

13.9

0.2

Oedema peripheralt

Very common

10.4

0.4

Injury, poisoning and procedural complications

Infusion-related reactionu

Common

1.3

0

a Includes nasopharyngitis, pharyngitis, rhinitis, tracheobronchitis and upper respiratory tract infection.

b Includes pneumocystis jirovecii pneumonia and pneumonia.

c Includes periodontitis, pulpitis dental, tooth abscess and tooth infection.

d Reported in studies outside of the HCC pool. Frequency is based on the POSEIDON study.

e Includes blood thyroid stimulating hormone increased, hypothyroidism and immune-mediated hypothyroidism.

f Includes blood thyroid stimulating hormone decreased and hyperthyroidism.

g Includes autoimmune thyroiditis, immune-mediated thyroiditis, thyroiditis and thyroiditis subacute.

h Reported in studies outside of the HCC pool. Frequency is based on a pooled data set of patients treated with tremelimumab in combination with durvalumab.

i Reported in studies outside of the POSEIDON study and HCC pool. Frequency is based on a pooled data set of patients treated with tremelimumab in combination with durvalumab.

j Includes autoimmune myocarditis.

k Includes immune-mediated pneumonitis and pneumonitis.

l Includes abdominal pain, abdominal pain lower, abdominal pain upper and flank pain.

m Includes colitis, enteritis and enterocolitis

n Includes pancreatitis and pancreatitis acute.

o Includes alanine aminotransferase increased, aspartate aminotransferase increased, hepatic enzyme increased and transaminases increased.

p Includes autoimmune hepatitis, hepatitis, hepatocellular injury, hepatotoxicity and immune-mediated hepatitis.

q Includes eczema, erythema, rash, rash macular, rash maculopapular, rash papular and rash pruritic.

r Includes dermatitis and immune-mediated dermatitis.

s Includes autoimmune nephritis and immune-mediated nephritis.

t Includes oedema peripheral and peripheral swelling.

u Includes infusion-related reaction and urticaria.

Description of selected adverse reactions

The data below also reflects information for significant adverse reactions for tremelimumab 300 mg in combination with durvalumab in the HCC pool (n=462).

The management guidelines for these adverse reactions are described in section 4.4.

Immune-mediated pneumonitis

In the HCC pool (n=462), immune-mediated pneumonitis occurred in 6 (1.3%) patients, including Grade 3 in 1 (0.2%) patient and Grade 5 (fatal) in 1 (0.2%) patient. The median time to onset was 29 days (range: 5-774 days). All patients received systemic corticosteroids, and 5 of the 6 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). One patient also received other immunosuppressants. Treatment was discontinued in 2 patients. Resolution occurred in 3 patients.

Immune-mediated hepatitis

In the HCC pool (n=462), immune-mediated hepatitis occurred in 34 (7.4%) patients, including Grade 3 in 20 (4.3%) patients, Grade 4 in 1 (0.2%) patient and Grade 5 (fatal) in 3 (0.6%) patients. The median time to onset was 29 days (range: 13-313 days). All patients received systemic corticosteroids, and 32 of the 34 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Nine patients also received other immunosuppressants. Treatment was discontinued in 10 patients. Resolution occurred in 13 patients.

Immune-mediated colitis

In the HCC pool (n=462), immune-mediated colitis or diarrhoea occurred in 31 (6.7%) patients, including Grade 3 in 17 (3.7%) patients. The median time to onset was 23 days (range: 2-479 days). All patients received systemic corticosteroids, and 28 of the 31 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Four patients also received other immunosuppressants. Treatment was discontinued in 5 patients. Resolution occurred in 29 patients.

Intestinal perforation was observed in patients receiving tremelimumab in combination with durvalumab (rare) in studies outside of the HCC pool.

Immune-mediated endocrinopathies

Immune-mediated hypothyroidism

In the HCC pool (n=462), immune-mediated hypothyroidism occurred in 46 (10.0%) patients. The median time to onset was 85 days (range: 26-763 days). One patient received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). All patients required other therapy including hormone replacement therapy. Resolution occurred in 6 patients. Immune-mediated hypothyroidism was preceded by immune-mediated hyperthyroidism in 4 patients.

Immune-mediated hyperthyroidism

In the HCC pool (n=462), immune-mediated hyperthyroidism occurred in 21 (4.5%) patients, including Grade 3 in 1 (0.2%) patient. The median time to onset was 30 days (range: 13-60 days). Four patients received systemic corticosteriods, and all of the four patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Twenty patients required other therapy (thiamazole, carbimazole, propylthiouracil, perchlorate, calcium channel blocker, or beta-blocker). One patient discontinued treatment due to hyperthyroidism. Resolution occurred in 17 patients.

Immune-mediated thyroiditis

In the HCC pool (n=462), immune-mediated thyroiditis occurred in 6 (1.3%) patients. The median time to onset was 56 days (range: 7-84 days). Two patients received systemic corticosteroids, and 1 of the 2 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). All patients required other therapy including hormone replacement therapy. Resolution occurred in 2 patients.

Immune-mediated adrenal insufficiency

In the HCC pool (n=462), immune-mediated adrenal insufficiency occurred in 6 (1.3%) patients, including Grade 3 in 1 (0.2%) patient. The median time to onset was 64 days (range: 43-504 days). All patients received systemic corticosteroids, and 1 of the 6 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Resolution occurred in 2 patients.

Immune-mediated type 1 diabetes mellitus

Immune-mediated type 1 diabetes mellitus was observed in patients receiving tremelimumab in combination with durvalumab (uncommon) in studies outside of the HCC pool.

Immune-mediated hypophysitis/hypopituitarism

In the HCC pool (n=462), immune-mediated hypophysitis/hypopituitarism occurred in 5 (1.1%) patients. The median time to onset for the events was 149 days (range: 27-242 days). Four patients received systemic corticosteroids, and 1 of the 4 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Three patients also required endocrine therapy. Resolution occurred in 2 patients.

Immune-mediated nephritis

In the HCC pool (n=462), immune-mediated nephritis occurred in 4 (0.9%) patients, including Grade 3 in 2 (0.4%) patients. The median time to onset was 53 days (range: 26-242 days). All patients received systemic corticosteroids, and 3 of the 4 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Treatment was discontinued in 2 patients. Resolution occurred in 3 patients.

Immune-mediated rash

In the HCC pool (n=462), immune-mediated rash or dermatitis (including pemphigoid) occurred in 26 (5.6%) patients, including Grade 3 in 9 (1.9%) patients and Grade 4 in 1 (0.2%) patient. The median time to onset was 25 days (range: 2-933 days). All patients received systemic corticosteroids and 14 of the 26 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). One patient received other immunosuppressants. Treatment was discontinued in 3 patients. Resolution occurred in 19 patients.

Immunogenicity

As with all therapeutic proteins, there is a potential for immunogenicity. Immunogenicity of tremelimumab is based on pooled data in 2075 patients who were treated with tremelimumab 75 mg or 1 mg/kg and evaluable for the presence of anti-drug antibodies (ADAs). Two-hundred fifty-two patients (12.1%) tested positive for treatment-emergent ADAs. Neutralising antibodies against tremelimumab were detected in 10.0% (208/2075) patients. The presence of ADAs did not impact tremelimumab pharmacokinetics, and there was no apparent effect on safety.

In the HIMALAYA study, of the 182 patients who were treated with tremelimumab 300 mg as a single dose in combination with durvalumab and evaluable for the presence of ADAs against tremelimumab, 20 (11.0%) patients tested positive for treatment-emergent ADAs. Neutralising antibodies against tremelimumab were detected in 4.4% (8/182) patients. The presence of ADAs did not have an apparent effect on pharmacokinetics or safety.

Elderly

Data from HCC patients 75 years of age or older are limited.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:

Yellow Card Scheme

Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

There is no information on overdose with tremelimumab. In case of overdose, patients should be closely monitored for signs or symptoms of adverse reactions, and appropriate symptomatic treatment instituted immediately.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Other monoclonal antibodies and antibody drug conjugates. ATC code: L01FX20

Mechanism of action

Cytotoxic T lymphocyte-associated antigen (CTLA-4) is primarily expressed on the surface of T lymphocytes. Interaction of CTLA-4 with its ligands, CD80 and CD86, limits effector T-cell activation, through a number of potential mechanisms, but primarily by limiting co-stimulatory signalling through CD28.

Tremelimumab is a selective, fully human IgG2 antibody that blocks CTLA-4 interaction with CD80 and CD86, thus enhancing T-cell activation and proliferation, resulting in increased T-cell diversity and enhanced anti-tumour activity.

The combination of tremelimumab, a CTLA-4 inhibitor and durvalumab, a PD-L1 inhibitor results in improved anti-tumour responses in metastatic non-small cell lung cancer and hepatocellular carcinoma.

Clinical efficacy

HCC - HIMALAYA Study

The efficacy of IMJUDO 300 mg as a single dose in combination with durvalumab was evaluated in the HIMALAYA Study, a randomised, open-label, multicentre study in patients with confirmed uHCC who did not receive prior systemic treatment for HCC. The study included patients with Barcelona Clinic Liver Cancer (BCLC) Stage C or B (not eligible for locoregional therapy) and Child-Pugh Score Class A.

The study excluded patients with brain metastases or a history of brain metastases, co-infection of viral hepatitis B and hepatitis C; active or prior documented gastro-intestinal (GI) bleeding within 12 months; ascites requiring non-pharmacologic intervention within 6 months; hepatic encephalopathy within 12 months before the start of treatment; active or prior documented autoimmune or inflammatory disorders.

Patients with esophageal varices were included except those with active or prior documented GI bleeding within 12 months prior to study entry.

Randomisation was stratified by macrovascular invasion (MVI) (yes vs. no), aetiology of liver disease (confirmed hepatitis B virus vs. confirmed hepatitis C virus vs. others) and ECOG performance status (0 vs. 1). The HIMALAYA study randomised 1171 patients 1:1:1 to receive:

• Durvalumab 1500 mg every 4 weeks

• IMJUDO 300 mg as a single dose + durvalumab 1500 mg; followed by durvalumab 1500 mg every 4 weeks

• Sorafenib 400 mg twice daily

Tumour assessments were conducted every 8 weeks for the first 12 months and then every 12 weeks thereafter. Survival assessments were conducted every month for the first 3 months following treatment discontinuation and then every 2 months.

The primary endpoint was Overall Survival (OS) for the comparison of IMJUDO 300 mg as a single dose in combination with durvalumab vs. sorafenib. Secondary endpoints included Progression-Free Survival (PFS), Investigator-assessed Objective Response Rate (ORR) and Duration of Response (DoR) according to RECIST v1.1.

The demographics and baseline disease characteristics were well balanced between study arms. The baseline demographics of the overall study population were as follows: male (83.7%), age < 65 years (50.4%), White (44.6%), Asian (50.7%), Black or African American (1.7%), Other race (2.3%), ECOG PS 0 (62.6%); Child-Pugh Class score A (99.5%), macrovascular invasion (25.2%), extrahepatic spread (53.4%), baseline AFP < 400 ng/ml (63.7%), baseline AFP ≥ 400 ng/ml (34.5%), viral aetiology; hepatitis B (30.6%), hepatitis C (27.2%), uninfected (42.2%), evaluable PD-L1 data (86.3%), PD-L1 Tumour area positivity (TAP) ≥ 1% (38.9%), PD-L1 TAP < 1% (48.3%) [Ventana PD-L1 (SP263) assay].

Results are presented in Table 4 and Figure 1.

Table 4. Efficacy results for the HIMALAYA study for IMJUDO 300 mg with durvalumab vs. Sorafenib

IMJUDO 300 mg + durvalumab

(n= 393)

Sorafenib

(n= 389)

Follow-up duration

Median follow-up (months)a

33.2

32.2

OS

Number of deaths (%)

262 (66.7)

293 (75.3)

Median OS (months)

(95% CI)

16.4

(14.2, 19.6)

13.8

(12.3, 16.1)

HR (95% CI)

0.78 (0.66, 0.92)

p-valueb

0.0035

PFS

Number of events (%)

335 (85.2)

327 (84.1)

Median PFS (months)

(95% CI)

3.78

(3.68, 5.32)

4.07

(3.75, 5.49)

HR (95% CI)

0.90 (0.77, 1.05)

ORR

ORR n (%)c

79 (20.1)

20 (5.1)

Complete Response n (%)

12 (3.1)

0

Partial Response n (%)

67 (17.0)

20 (5.1)

DoR

Median DoR (months)

22.3

18.4

a Calculated using the reverse Kaplan-Meier technique (with censor indicator reversed).

b Based on a Lan-DeMets alpha spending function with O'Brien Fleming type boundary and the actual number of events observed, the boundary for declaring statistical significance for IMJUDO 300 mg + durvalumab vs. Sorafenib was 0.0398 (Lan◦and◦DeMets 1983).

c Confirmed complete response.

CI=Confidence Interval

Figure 1. Kaplan-Meier curve of OS

Paediatric population

The Licensing Authority has deferred the obligation to submit the results of studies with tremelimumab in all subsets of the paediatric population in the treatment of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms). See section 4.2 for information on paediatric use.

5.2 Pharmacokinetic properties

The pharmacokinetics (PK) of tremelimumab was assessed for tremelimumab as monotherapy and in combination with durvalumab.

The PK of tremelimumab was studied in patients with doses ranging from 75 mg to 750 mg or 10 mg/kg administered intravenously once every 4 or 12 weeks as monotherapy, or at a single dose of 300 mg. PK exposure increased dose proportionally (linear PK) at doses ≥ 75 mg. Steady state was achieved at approximately 12 weeks. Based on population PK analysis that included patients (n = 1605) who received tremelimumab monotherapy or in combination with other medicinal products in the dose range of ≥ 75 mg (or 1 mg/kg) every 3 or 4 weeks, the estimated tremelimumab clearance (CL) and volume of distribution (Vd) were 0.309 l/day and 6.33 l, respectively. The terminal half-life was approximately 14.2 days. The primary elimination pathways of tremelimumab are protein catabolism via reticuloendothelial system or target mediated disposition.

Special populations

Age (18–87 years), body weight (34-149 kg), gender, positive anti-drug antibody (ADA) status, albumin levels, LDH levels, creatinine levels, tumour type, race or ECOG/WHO status had no clinically significant effect on the PK of tremelimumab.

Renal impairment

Mild (creatinine clearance (CrCL) 60 to 89 ml/min) and moderate renal impairment (creatinine clearance (CrCL) 30 to 59 ml/min) had no clinically significant effect on the PK of tremelimumab. The effect of severe renal impairment (CrCL 15 to 29 ml/min) on the PK of tremelimumab is unknown; the potential need for dose adjustment cannot be determined. However, as IgG monoclonal antibodies are not primarily cleared via renal pathways, a change in renal function is not expected to influence tremelimumab exposure.

Hepatic impairment

Mild hepatic impairment (bilirubin ≤ ULN and AST > ULN or bilirubin > 1.0 to 1.5 × ULN and any AST) and moderate hepatic impairment (bilirubin > 1.5 to 3 x ULN and any AST) had no clinically significant effect on the PK of tremelimumab. The effect of severe hepatic impairment (bilirubin > 3.0 x ULN and any AST) on the PK of tremelimumab is unknown; the potential need for dose adjustement cannot be determined. However, as IgG monoclonal antibodies are not primarily cleared via hepatic pathways, a change in hepatic function is not expected to influence tremelimumab exposure.

5.3 Preclinical safety data

Animal toxicology

In the chronic 6-month study in cynomolgus monkeys, treatment with tremelimumab was associated with dose-related incidence in persistent diarrhoea and skin rash, scabs and open sores, which were dose-limiting. These clinical signs were also associated with decreased appetite and body weight and swollen peripheral lymph nodes. Histopathological findings correlating with the observed clinical signs included reversible chronic inflammation in the cecum and colon, mononuclear cell infiltration in the skin and hyperplasia in lymphoid tissues.

A dose-dependent increase in the incidence and severity of mononuclear cell infiltration with or without mononuclear cell inflammation was observed in the salivary gland, pancreas (acinar), thyroid, parathyroid, adrenal, heart, esophagus, tongue, periportal liver area, skeletal muscle, prostate, uterus, pituitary, eye (conjunctiva, extra ocular muscles), and choroid plexus of the brain. No NOAEL was found in this study with animals treated with the lowest dose of 5 mg/kg/week, however the intermediate dose of 15 mg/kg week was considered the highest non-severely toxic dose (HNSTD). This dose provided an exposure-based safety margin of 1.77-5.33 to clinical relevant exposure based on the clinical dosing regimen of either a 300 mg single dose or 75 mg every three weeks.

Carcinogenicity and mutagenicity

The carcinogenic and genotoxic potential of tremelimumab has not been evaluated.

Reproductive toxicology

Mononuclear cell infiltration in prostate and uterus was observed in repeat dose toxicity studies. Since animal fertility studies have not been conducted with tremelimumab, the relevance of these findings for fertility is unknown. In reproduction studies, administration of tremelimumab to pregnant cynomolgus monkeys during the period of organogenesis was not associated with maternal toxicity or effects on pregnancy losses, foetal weights, or external, visceral, skeletal abnormalities or weights of selected foetal organs.

6. Pharmaceutical particulars
6.1 List of excipients

Histidine

Histidine hydrochloride monohydrate

Trehalose dihydrate

Disodium edetate dihydrate

Polysorbate 80

Water for injections

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

6.3 Shelf life

Unopened vial

4 years at 2 °C - 8 °C.

Diluted solution

Chemical and physical in-use stability has been demonstrated for up to 28 days at 2 °C to 8 °C and for up to 48 hours at room temperature (up to 25 °C) from the time of preparation.

From a microbiological point of view, the prepared solution for infusion should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 °C to 8 °C or 12 hours at room temperature (up to 25 °C), unless dilution has taken place in controlled and validated aseptic conditions.

Lack of microbial growth in the prepared solution for infusion has been demonstrated for up to 28 days at 2 °C to 8 °C and for up to 48 hours at room temperature (up to 25 °C) from the time of preparation.

6.4 Special precautions for storage

Store in a refrigerator (2 °C - 8 °C).

Do not freeze.

Store in the original package in order to protect from light.

For storage conditions after dilution of the medicinal product, see section 6.3.

6.5 Nature and contents of container

Two pack sizes of IMJUDO are available:

• 1.25 ml (a total of 25 mg tremelimumab) concentrate in a Type I glass vial with an elastomeric stopper and a violet flip-off aluminum seal. Pack size of 1 single-dose vial.

• 15 ml (a total of 300 mg tremelimumab) concentrate in a Type I glass vial with an elastomeric stopper and a dark blue flip-off aluminum seal. Pack size of 1 single-dose vial.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

Preparation of solution

IMJUDO is supplied as a single-dose vial and does not contain any preservatives, aseptic technique must be observed.

• Visually inspect medicinal product for particulate matter and discolouration. IMJUDO is clear to slightly opalescent, colourless to slightly yellow solution. Discard the vial if the solution is cloudy, discoloured or visible particles are observed. Do not shake the vial.

• Withdraw the required volume from the vial(s) of IMJUDO and transfer into an intravenous bag containing sodium chloride 9 mg/ml (0.9%) solution for injection, or glucose 50 mg/ml (5%) solution for injection. Mix diluted solution by gentle inversion. The final concentration of the diluted solution should be between 0.1 mg/ ml and 10 mg/ml. Do not freeze or shake the solution.

• Care must be taken to ensure the sterility of the prepared solution.

• Do not re-enter the vial after withdrawal of the medicinal product.

• Discard any unused portion left in the vial.

Administration

• Administer the infusion solution intravenously over 60 minutes through an intravenous line containing a sterile, low-protein binding 0.2 or 0.22 micron in-line filter.

• Do not co-administer other medicinal products through the same infusion line.

Disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. Marketing authorisation holder

AstraZeneca UK Limited,

1 Francis Crick Avenue,

Cambridge,

CB2 0AA,

UK.

8. Marketing authorisation number(s)

PLGB 17901/0368

9. Date of first authorisation/renewal of the authorisation

Date of first authorisation: 06 June 2023

10. Date of revision of the text

09/02/2024

AstraZeneca UK Limited
Company image
Address
2 Pancras Square, 8th Floor, London, N1C 4AG, UK
Telephone
+44 (0)1582 836 000
Fax
+44 (0)1582 838 000
Medical Information Direct Line
0800 783 0033
Medical Information e-mail
[email protected]
Medical Information Fax
+44 (0)1582 838 003
Medical Information Website
https://medicalinformation.astrazeneca.co.uk/
Medical Information Website
www.myazmed.co.uk